Sinco Pharma Reports Stable Share Capital and Confirms Public Float Compliance for May 2026

Bulletin Express06-01

Hong Kong, 1 June 2026 — Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) filed its monthly return for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.

Authorised Share Capital • Ordinary shares authorised: 10.00 billion, par value HKD 0.0001 each, representing authorised capital of HKD 1.00 million. • No increase or decrease was recorded in May 2026.

Issued Share Capital • Issued ordinary shares: 2.03 billion, identical to the prior month. • The company held no treasury shares and executed no share issuances, cancellations, or buy-backs in May.

Public Float • Sinco Pharma affirmed compliance with the Main Board’s minimum public-float threshold of 25 % of issued shares.

Share Option Scheme • The share option scheme adopted on 26 May 2025 showed: – Outstanding options at month-end: nil. – New grants, exercises, cancellations, or lapses: none. – Shares available for future option grants: 203.29 million.

No warrants, convertible securities, or other equity-linked instruments were outstanding or issued during the month.

The filing was submitted by Company Secretary Peng Yunlu, confirming adherence to all applicable listing and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1112791148?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-01 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1112791148","market":"hk","top_or_hot":-1,"title":"Sinco Pharma Reports Stable Share Capital and Confirms Public Float Compliance for May 2026","media":"Bulletin Express","content":"<p>Hong Kong, 1 June 2026 — Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) filed its monthly return for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.</p>\n<p>Authorised Share Capital  \n• Ordinary shares authorised: 10.00 billion, par value HKD 0.0001 each, representing authorised capital of HKD 1.00 million.  \n• No increase or decrease was recorded in May 2026.</p>\n<p>Issued Share Capital  \n• Issued ordinary shares: 2.03 billion, identical to the prior month.  \n• The company held no treasury shares and executed no share issuances, cancellations, or buy-backs in May.</p>\n<p>Public Float  \n• Sinco Pharma affirmed compliance with the Main Board’s minimum public-float threshold of 25 % of issued shares.</p>\n<p>Share Option Scheme  \n• The share option scheme adopted on 26 May 2025 showed:  \n  – Outstanding options at month-end: nil.  \n  – New grants, exercises, cancellations, or lapses: none.  \n  – Shares available for future option grants: 203.29 million.</p>\n<p>No warrants, convertible securities, or other equity-linked instruments were outstanding or issued during the month.</p>\n<p>The filing was submitted by Company Secretary Peng Yunlu, confirming adherence to all applicable listing and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sinco Pharma Reports Stable Share Capital and Confirms Public Float Compliance for May 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSinco Pharma Reports Stable Share Capital and Confirms Public Float Compliance for May 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-01 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hong Kong, 1 June 2026 — Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) filed its monthly return for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.</p>\n<p>Authorised Share Capital  \n• Ordinary shares authorised: 10.00 billion, par value HKD 0.0001 each, representing authorised capital of HKD 1.00 million.  \n• No increase or decrease was recorded in May 2026.</p>\n<p>Issued Share Capital  \n• Issued ordinary shares: 2.03 billion, identical to the prior month.  \n• The company held no treasury shares and executed no share issuances, cancellations, or buy-backs in May.</p>\n<p>Public Float  \n• Sinco Pharma affirmed compliance with the Main Board’s minimum public-float threshold of 25 % of issued shares.</p>\n<p>Share Option Scheme  \n• The share option scheme adopted on 26 May 2025 showed:  \n  – Outstanding options at month-end: nil.  \n  – New grants, exercises, cancellations, or lapses: none.  \n  – Shares available for future option grants: 203.29 million.</p>\n<p>No warrants, convertible securities, or other equity-linked instruments were outstanding or issued during the month.</p>\n<p>The filing was submitted by Company Secretary Peng Yunlu, confirming adherence to all applicable listing and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06833","symbol_name":"兴科蓉医药","start_time":0,"source_url":"","article_id":"1112791148","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1112791148","pubTimestamp":1780303633,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hong Kong, 1 June 2026 — Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) filed its monthly return for the period ended 31 May 2026, confirming that both authorised and issued share capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06833":"兴科蓉医药"},"translate_title":"Sinco Pharma报告股本稳定并确认2026年5月公众持股量合规","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06833":1},"content_text":"Hong Kong, 1 June 2026 — Sinco Pharmaceuticals Holdings Limited (Sinco Pharma) filed its monthly return for the period ended 31 May 2026, confirming that both authorised and issued share capital remained unchanged during the month.\nAuthorised Share Capital  \n• Ordinary shares authorised: 10.00 billion, par value HKD 0.0001 each, representing authorised capital of HKD 1.00 million.  \n• No increase or decrease was recorded in May 2026.\nIssued Share Capital  \n• Issued ordinary shares: 2.03 billion, identical to the prior month.  \n• The company held no treasury shares and executed no share issuances, cancellations, or buy-backs in May.\nPublic Float  \n• Sinco Pharma affirmed compliance with the Main Board’s minimum public-float threshold of 25 % of issued shares.\nShare Option Scheme  \n• The share option scheme adopted on 26 May 2025 showed:  \n  – Outstanding options at month-end: nil.  \n  – New grants, exercises, cancellations, or lapses: none.  \n  – Shares available for future option grants: 203.29 million.\nNo warrants, convertible securities, or other equity-linked instruments were outstanding or issued during the month.\nThe filing was submitted by Company Secretary Peng Yunlu, confirming adherence to all applicable listing and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1112791148","isCrawlerRequest":true}